Alto Neuroscience (ANRO) Accumulated Expenses (2023 - 2026)

Alto Neuroscience (ANRO) has 4 years of Accumulated Expenses data on file, last reported at $7.6 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 29.58% year-over-year to $7.6 million; the trailing twelve-month figure through Mar 2026 stood at $7.6 million (up 29.58% YoY), and the FY2025 full-year result was $8.9 million, up 5.14% from the prior year.
• Accumulated Expenses eased to $7.6 million in Q1 2026, from $8.9 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $8.9 million in Q4 2025 to a low of $4.4 million in Q1 2024.
• A 4-year average of $6.7 million and a median of $6.7 million in 2025 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses surged 85.82% in 2024 and dropped 15.16% in 2025, its largest moves.
• Tracing ANRO's Accumulated Expenses over 4 years: stood at $4.5 million in 2023, then soared by 85.82% to $8.4 million in 2024, then rose by 5.14% to $8.9 million in 2025, then retreated by 14.13% to $7.6 million in 2026.
• Business Quant data shows ANRO's Accumulated Expenses at $7.6 million in Q1 2026, $8.9 million in Q4 2025, and $7.0 million in Q3 2025.